These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38675131)

  • 1. First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration.
    Aljundi W; Daas L; Suffo S; Seitz B; Abdin AD
    Pharmaceutics; 2024 Mar; 16(4):. PubMed ID: 38675131
    [No Abstract]   [Full Text] [Related]  

  • 2. Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration.
    Aljundi W; Munteanu C; Seitz B; Abdin AD
    Graefes Arch Clin Exp Ophthalmol; 2024 Apr; ():. PubMed ID: 38607409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
    Kataoka K; Itagaki K; Hashiya N; Wakugawa S; Tanaka K; Nakayama M; Yamamoto A; Mukai R; Honjyo J; Maruko I; Kawai M; Miyara Y; Terao N; Wakatsuki Y; Onoe H; Mori R; Koizumi H; Sekiryu T; Iida T; Okada AA;
    Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):43-51. PubMed ID: 37668741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
    Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up).
    Abdin AD; Hanifa O; Aljundi W; Munteanu C; Seitz B; Suffo S
    Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):457-468. PubMed ID: 37864635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration.
    Kishi M; Miki A; Kamimura A; Okuda M; Matsumiya W; Imai H; Kusuhara S; Nakamura M
    J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME).
    Giancipoli E; Guglielmi A; Bux AV; Clima GME; Pignatelli F; Boscia F; Viggiano P; Boscia G; Fortunato F; Besozzi G; Niro A; Dore S; Iaculli C
    Ophthalmol Ther; 2024 Aug; 13(8):2163-2184. PubMed ID: 38831127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
    Matsumoto H; Hoshino J; Nakamura K; Akiyama H
    Jpn J Ophthalmol; 2024 Mar; 68(2):83-90. PubMed ID: 38244172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration.
    Abdin AD; Aljundi W; El Jawhari K; Suffo S; Weinstein I; Seitz B
    Front Pharmacol; 2022; 13():860784. PubMed ID: 35721125
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
    Karasu B; Gunay BO
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis.
    Yen WT; Wu CS; Yang CH; Chen YH; Lee CH; Hsu CR
    Sci Rep; 2024 Jan; 14(1):2485. PubMed ID: 38291069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subfoveal Choroidal Thickness as a Potential Predictor of Clinical Response to Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration.
    Ranjbar M; Kurz M; Holzhey A; Rades D; Grisanti S
    Ophthalmic Surg Lasers Imaging Retina; 2018 May; 49(5):320-328. PubMed ID: 29772042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
    Matsumoto H; Hoshino J; Nakamura K; Nagashima T; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2023 Oct; 261(10):2945-2952. PubMed ID: 37195339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment.
    Takahashi H; Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Kawashima H; Yanagi Y
    Sci Rep; 2024 Apr; 14(1):9087. PubMed ID: 38643252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brolucizumab Intravitreal Injection in Macular Neovascularization Type 1: VA, SD-OCT, and OCTA Parameter Changes during a 16-Week Follow-Up.
    Toto L; Ruggeri ML; D'Aloisio R; De Nicola C; Trivigno C; Cerino L; Di Marzio G; Di Nicola M; Porreca A; Mastropasqua R
    Ophthalmic Res; 2023; 66(1):218-227. PubMed ID: 36162382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema.
    Ünlü C; Erdogan G; Gunay BO; Kardes E; Akcay BI; Ergin A
    Int Ophthalmol; 2017 Feb; 37(1):147-158. PubMed ID: 27154721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Loading Dose between Aflibercept and Faricimab for Neovascular Age-Related Macular Degeneration.
    Hara C; Suzue M; Fujimoto S; Fukushima Y; Sayanagi K; Nishida K; Maruyama K; Sato S; Nishida K
    J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration.
    Ng B; Kolli H; Ajith Kumar N; Azzopardi M; Logeswaran A; Buensalido J; Mushtaq B; Chavan R; Chong YJ
    Life (Basel); 2024 Jan; 14(2):. PubMed ID: 38398702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kang EC; Choi S; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2157-2163. PubMed ID: 28819823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy.
    Szigiato A; Mohan N; Talcott KE; Mammo DA; Babiuch AS; Kaiser PK; Ehlers JP; Rachitskaya A; Yuan A; Srivastava SK; Sharma S
    Ophthalmol Retina; 2024 Jan; 8(1):10-17. PubMed ID: 37673396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.